Trial Profile
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Vercirnon (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms SHIELD-3
- Sponsors GlaxoSmithKline; GSK
- 16 Jan 2022 This trial has been completed in Estonia, according to European Clinical Trials Database record.
- 10 Jan 2014 Status changed from suspended to discontinued according to ClinicalTrials.gov record.
- 23 Aug 2013 Status changed from recruiting to suspended, according to a GlaxoSmithKline media release. New recruitment and dosing has been suspended pending further review.